XML 269 R37.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting, Measurement Disclosures [Abstract]  
Detailed Segment Data Detailed segment data is as follows ($ in millions):
BiotechnologyLife SciencesDiagnosticsTotal Reportable Segments
Other(a)
Total Company
Year Ended December 31, 2025
Sales (GAAP)$7,293 $7,334 $9,941 $24,568 $— $24,568 
Less:
Depreciation(149)(185)(407)(741)(9)(750)
Amortization of intangible assets(902)(604)(191)(1,697)— (1,697)
Impairments(b)
(101)(446)(15)(562)— (562)
Other segment items(c)
(4,277)(5,579)(6,678)(16,534)(335)(16,869)
Operating profit$1,864 $520 $2,650 $5,034 $(344)$4,690 
Year Ended December 31, 2024
Sales (GAAP)$6,759 $7,329 $9,787 $23,875 $— $23,875 
Less:
Depreciation(151)(167)(394)(712)(9)(721)
Amortization of intangible assets(863)(576)(192)(1,631)— (1,631)
Impairments(b)
— (222)(43)(265)— (265)
Other segment items(c)
(4,060)(5,485)(6,533)(16,078)(317)(16,395)
Operating profit$1,685 $879 $2,625 $5,189 $(326)$4,863 
Year Ended December 31, 2023
Sales (GAAP)$7,172 $7,141 $9,577 $23,890 $— $23,890 
Less:
Depreciation(162)(129)(379)(670)(5)(675)
Amortization of intangible assets(864)(429)(198)(1,491)— (1,491)
Impairments(b)
(54)— (23)(77)— (77)
Other segment items(c)
(4,183)(5,374)(6,571)(16,128)(317)(16,445)
Operating profit$1,909 $1,209 $2,406 $5,524 $(322)$5,202 
(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.
(b) For information on the impairments, refer to Note 10.
(c) Other segment items for each reportable segment include cost of sales, SG&A expenses and R&D expenses, excluding depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.
The following table presents identifiable assets as of the years ended December 31 ($ in millions):
202520242023
Biotechnology$37,337 $34,605 $37,421 
Life Sciences23,112 23,211 23,730 
Diagnostics14,748 14,204 14,552 
Other8,267 5,522 8,785 
Total$83,464 $77,542 $84,488 
The following table presents capital expenditures, gross for the years ended December 31 ($ in millions):
202520242023
Biotechnology$370 $447 $417 
Life Sciences186 391 320 
Diagnostics592 550 546 
Other8 4 100 
Total$1,156 $1,392 $1,383 
Schedule of Operations in Geographical Areas
Operations in Geographical Areas:
Year Ended December 31
($ in millions)202520242023
Sales:
United States$9,981 $9,927 $9,579 
China2,631 2,805 3,143 
All other (each country individually less than 5% of total sales)
11,956 11,143 11,168 
Total$24,568 $23,875 $23,890 
Property, plant and equipment, net:
United States$2,757 $2,585 $2,304 
United Kingdom586 519 371 
Sweden477 384 425 
Germany287 251 238 
All other (each country individually less than 5% of total property, plant and equipment, net)
1,424 1,251 1,215 
Total$5,531 $4,990 $4,553